DK184890D0 - Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme - Google Patents

Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme

Info

Publication number
DK184890D0
DK184890D0 DK184890A DK184890A DK184890D0 DK 184890 D0 DK184890 D0 DK 184890D0 DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A DK 184890 D0 DK184890 D0 DK 184890D0
Authority
DK
Denmark
Prior art keywords
immunotoxin
auto
cell
preparation
treatment
Prior art date
Application number
DK184890A
Other languages
English (en)
Other versions
DK184890A (da
Inventor
Patrick J Scannon
Richard C Harmon
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of DK184890D0 publication Critical patent/DK184890D0/da
Publication of DK184890A publication Critical patent/DK184890A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK184890A 1988-02-03 1990-08-02 Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme DK184890A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15174488A 1988-02-03 1988-02-03
PCT/US1989/000440 WO1989006968A1 (en) 1988-02-03 1989-02-03 Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Publications (2)

Publication Number Publication Date
DK184890D0 true DK184890D0 (da) 1990-08-02
DK184890A DK184890A (da) 1990-10-03

Family

ID=22540082

Family Applications (1)

Application Number Title Priority Date Filing Date
DK184890A DK184890A (da) 1988-02-03 1990-08-02 Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme

Country Status (5)

Country Link
EP (1) EP0397798A4 (da)
JP (1) JPH03503887A (da)
AU (1) AU633251B2 (da)
DK (1) DK184890A (da)
WO (1) WO1989006968A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225372A (en) * 1987-07-17 1991-04-26 Xoma Corp Immunotoxin composition comprising purified ricin-a-chain species
ES2077670T3 (es) * 1988-12-13 1995-12-01 Univ Florida Metodos y composiciones que sirven para la deteccion precoz y el tratamiento de la diabetes mellitus dependiente de la insulina.
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
PT93337B (pt) * 1989-03-06 1997-01-31 Univ California Ensaio para o tratamento e doencas autoimunitarias
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
IL98932A0 (en) * 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
IT1249051B (it) * 1991-02-26 1995-02-11 Italfarmaco Spa Immunotossina da anticorpi monoclonali anti-cd5
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
JP4157160B2 (ja) * 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
AU733898B2 (en) 1997-03-05 2001-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxins and methods of inducing immune tolerance
EP1073463B1 (en) * 1998-04-22 2009-07-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
CN114206358A (zh) * 2019-06-05 2022-03-18 美真达治疗公司 T细胞消耗疗法
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
EP0232447A1 (en) * 1986-02-13 1987-08-19 Xoma Corporation Lectin immunotoxins
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy
EP0256471A3 (en) * 1986-08-15 1989-10-25 Xoma Corporation Cytotoxic conjugates for cancer therapy
DE3855236D1 (de) * 1987-08-17 1996-05-30 Us Commerce Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
WO1989006967A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions

Also Published As

Publication number Publication date
WO1989006968A1 (en) 1989-08-10
AU3215789A (en) 1989-08-25
EP0397798A4 (en) 1991-10-30
AU633251B2 (en) 1993-01-28
JPH03503887A (ja) 1991-08-29
DK184890A (da) 1990-10-03
EP0397798A1 (en) 1990-11-22

Similar Documents

Publication Publication Date Title
DK184890D0 (da) Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme
DK215987D0 (da) Farmaceutiske praeparater af syrelabile stoffer tiloral indgift
DK362189A (da) Farmaceutisk praeparat til intravenoes indgift
NO922005D0 (no) Farmasoeytiske preparater
DK263288D0 (da) Farmaceutisk praeparat af cefuroxim-axetil
DK333788D0 (da) Farmaceutisk praeparat til behandling af oedelagt bruskvaev
DK149988A (da) Stabile farmaceutiske praeparater
DK184087A (da) Farmaceutiske praeparater med forbedret biotilgaengelighed
DK413987D0 (da) Farmaceutiske praeparater
NO872551D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
DK397388A (da) Derivater af n-aminobutyl-n-phenylarylamider til terapeutisk anvendelse samt fremgangsmaade til fremstilling af saadanne derivater
DK652787D0 (da) Farmaceutiske praeparater
DK226488D0 (da) Anvendelse af ace-inhibitorer til fremstilling af farmaceutiske praeparater
NO874200D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
DK635988D0 (da) 1,3-butandiolacetoacetat-derivater og anvendelse af 1,3-butandiolacetoacetat-forbindelser til fremstilling af farmaceutiske praeparater
DK447887A (da) Frysetoerrede farmaceutiske praeparater
DK298389A (da) Farmaceutisk praeparat til topisk anvendelse omfattende et amin-funktionelt medikament
DK0458855T3 (da) Farmaceutisk præparat til behandling af tonsillitis
NO872233D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO875359D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO873423D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
DK701588D0 (da) N-hydroxy-5-phenyl-2-furancarboximidamider og anvendelse heraf til fremstilling af farmceutiske praeparater
DK500589D0 (da) Farmaceutisk praeparat til behandling af lungeobstruktioner
NO883663L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
DK149588A (da) Xylometazolinholdige farmaceutiske praeparater

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment